Biotech company Aura Biosciences has secured a $21 million Series B round of funding led by financing from Advent Life Sciences and both new and previous investors. The company is focused on using the money to further develop its mini-drug-delivery capsules (synthetic viruses). This technology was discovered and developed in partnership with Dr. John Schiller […]
A hot segment of targeted cancer therapy is using synthetic viruses, or pseudovirions, to serve as mini drug delivery capsules. These tiny protein shells are engineered to hone in to attack certain cancerous cells – avoiding healthy tissue completely. This model of treatment prevents the toxic cancers from affecting the non-cancerous parts of the body. Cambridge-based pseudovirion developer Aura […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.